NEW YORK (GenomeWeb) – Seattle-based Resolution Biosciences announced today that New York State's Clinical Laboratory Evaluation Program (NY CLEP) has granted regulatory approval for the company's ctDx Lung cancer assay, a targeted next-generation sequencing test that identifies actionable mutations in blood samples from non-small cell lung cancer patients.
President and CEO Mark Li said in a statement that the certification will allow Resolution to reach more patients, as well as ease the way for ongoing and planned clinical studies in New York.